SB 1023 (see companion bill HB 1194) – Maryland

Status: Inactive / Dead
Year Introduced: 2018
Link: http://mgaleg.maryland.gov/webmga/frmMain.aspx?id=sb1023&stab=01&pid=billpage&tab=subject3&ys=2018rs

ESTABLISHING THE DRUG COST REVIEW COMMISSION: Providing for the purpose and membership of the Commission to establish an all-payer drug rate setting program. Requires brand and generic manufacturers to report certain information to the commission if launch prices or price increases exceed certain thresholds. The commission, in consultation with stakeholders, would determine if drugs create affordability challenges in the state and if so, the commission would determine a reimbursement rate that would create affordability.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found

Leave A Comment